Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Gumarontinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Gumarontinib is a once-daily targeted tablet for a specific type of lung cancer driven by a change in the MET gene. It was discovered and developed in China by Shanghai Haihe Biopharma, and is sold there as 海益坦® (Haiyitan®). In earlier papers it was called glumetinib or SCC244.
China's National Medical Products Administration (NMPA) gave it conditional approval in March 2023 for adults with:
Japan's regulator approved it for the same type of lung cancer in June 2024. It is a prescription cancer medicine and should only be used under a medical oncologist.
In MET exon 14 lung cancer, a small piece of the MET receptor that normally acts as its "off switch" is missing, so the receptor stays active and keeps pushing the tumour to grow. Gumarontinib is a highly selective MET inhibitor: it blocks the receptor's activity and the growth signals that follow, which can shrink the tumour.
Approval was based on the phase 2 GLORY study, run at 42 hospitals in China and Japan and published in eClinicalMedicine in 2023. Of 79 patients whose MET mutation was confirmed centrally, 66% had their tumours shrink: 71% of those treated first-line and 60% of those treated before.
After longer follow-up (reported in 2025), the median time before the cancer grew again was 7.7 months and median overall survival was 19.4 months, rising to 25.4 months in people who had not had earlier treatment.
This dosing comes from the official Japanese prescribing information, which matches the GLORY trial. Your oncologist sets the exact plan.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Fluid build-up: swelling (oedema) affected 79.8% of patients in the GLORY study, and low blood albumin 38.1%. Fluid can also collect around the lungs (9.5%) or heart (2.4%). Report sudden weight gain, swelling or breathlessness to your doctor promptly.
Overall: severe (grade 3 or higher) treatment-related side effects occurred in 53.6% of patients, and 8.3% stopped treatment because of them. Safety in children has not been studied.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved in China and Japan only. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other MET-targeted lung cancer options, see our pages on Tepmetko and Emrelis.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each Chinese box holds 24 tablets of 50 mg, which is four days' supply at the usual 300 mg dose, so about seven to eight boxes cover a month. The tablets travel in their sealed original packs under temperature-controlled shipping and should be stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid specialist's prescription.
Lung cancer specialists in Delhi increasingly test for MET exon 14, and our New Delhi dispatch point means short delivery times.
Monthly supplies can be delivered to the hospital pharmacy or the patient's home on the oncologist's advice.
Oncologists in Bangalore can request the tablets for a named patient, with the full cost shared before ordering.
Patients from across Tamil Nadu treated in Chennai can receive sealed original packs with import documents.
We plan each month's boxes ahead so a once-daily course is never interrupted.
Deliveries reach Kolkata and the north-eastern states with tracking at every stage.
Patients in Pune can start the import as soon as the prescription and MET report are ready.
The treating oncologist can send us the papers directly to begin the process.
Patients treated in Vellore can have supply sent to the hospital for collection.
Covers patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We arrange deliveries to cancer centres in Lucknow and across Uttar Pradesh.
Patients across Kerala can receive their tablets in Kochi or nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
